TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00247715
Drug: pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00479999
Drug: VRC-HIVADV027-00-VP
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00479999
Drug: VRC-HIVADV038-00-VP
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02633007
Drug: Carbidopa
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally according to the carbidopa dosing schedule.
Study: NCT02242253
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered via HandiHaler®
Study: NCT02242253
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: administered via metered dose inhaler (MDI)
Study: NCT02321111
Drug: Eritoran
Normalized name: Eritoran
DrugBank: Eritoran (DB04933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
Study: NCT02321111
Drug: D5W (5% Dextrose in water)
Normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D5W = 5% Dextrose Water Vehicle
Study: NCT01799629
Drug: Glycerin suppositories
Normalized name: Glycerin Suppositories
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02877901
Drug: long acting tolterodine 4 mg
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive one tablet at bed time for 4 weeks
Study: NCT00608101
Drug: Fludrocortisone
Normalized name: Fludrocortisone
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
Study: NCT00608101
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
Study: NCT00596531
Drug: Acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration, 666 mg, tid, for 4 months
Study: NCT00350207
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00350207
Drug: Salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00300807
Drug: XTL 6865
Normalized name: XTL-6865
DrugBank: XTL-6865 (DB06058)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00663793
Drug: Acyline
Normalized name: Acyline
DrugBank: Acyline (DB11906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mcg/kg
Study: NCT00663793
Drug: Finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg PO once daily \[day -2 to day 12) 14 days total
Study: NCT03711188
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information.
Study: NCT03711188
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information.
Study: NCT03711188
Drug: IMM-101
Normalized name: IMM-101
DrugBank: IMM-101 (DB15850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
Study: NCT01831661
Drug: Metformin Hydrochloride Extended-Release Tablets USP 750 mg
Normalized name: metformin hydrochloride Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
Study: NCT00644215
Drug: 5-FU and Mitomycin
Normalized name: 5-FU
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 5-FU injection 5mg~* Mitomycin drop 0.02%
Study: NCT01269918
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
Study: NCT01723800
Drug: PI3K inhibitor BKM120
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01723800
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01723800
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04085237
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30ml of 0.375% ropivacaine with 5mcg/ml of epinephrine will be injected into the fascial plane on the anterior spinae muscle.
Study: NCT03571828
Drug: AMG 562
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
Study: NCT04466280
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg of hydroxychloroquine daily for participants in the intervention group 1
Study: NCT03743051
Drug: Anamorelin Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Anamorelin (DB06645)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
Study: NCT04570332
Drug: BO-112 plus pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with the combination of BO-112 and pembrolizumab. Order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles
Study: NCT00711087
Drug: BOTOX-A
Normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
Study: NCT01350362
Drug: tideglusib
Normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
Study: NCT01350362
Drug: tideglusib
Normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
Study: NCT01350362
Drug: tideglusib
Normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
Study: NCT00918866
Drug: Definity
Normalized name: Definity
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
Study: NCT00245466
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given as a subcutaneous injection once every 4 weeks.
Study: NCT04237376
Drug: Tenofovir Alafenamide 25 MG
Normalized name: tenofovir alafenamide 25 MG
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir Alafenamide 25 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
Study: NCT04237376
Drug: Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
Normalized name: TENOFOVIR DISOPROXIL FUMARATE 300 mg ORAL TABLET
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir Disoproxil Fumarate 300 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
Study: NCT01307865
Drug: injectable poly-L-lactic acid
Normalized name: L-Lactic acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.
Study: NCT00000468
Drug: tissue plasminogen activator
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02859766
Drug: Abicipar pegol
Normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
Study: NCT00160303
Drug: Prolotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01472692
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 80mg PO daily for 8 weeks
Study: NCT00100828
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02392117
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
Study: NCT01176513
Drug: GE-148 (18F)
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
Study: NCT00044408
Drug: Ruboxistaurin mesylate
Normalized name: mesylate
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00107848
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01509339
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
Study: NCT01753570
Drug: MP-424
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-424: 750mg every 8 hours (q8h) for 12 weeks
Study: NCT01753570
Drug: RBV(24 weeks)
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV: 600 - 1000mg/day based on body weight for 24 weeks
Study: NCT01753570
Drug: IFN beta(24 weeks)
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
Study: NCT01753570
Drug: RBV(48 weeks)
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV: 600 - 1000mg/day based on body weight for 48 weeks
Study: NCT01753570
Drug: IFN beta(48 weeks)
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks
Study: NCT03028428
Drug: Sodium Hyaluronate
Normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium hyaluronate administered into the knee joint once
Study: NCT04982861
Drug: Cefixime Trihydrate 100 mg/5 mL Dry Syrup
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received a single dose of 5 mL of cefixime dry syrup with 240 mL of water
Study: NCT00154661
Drug: pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01193777
Drug: L-Carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 gram bolus followed by 8 gram in 1 L NS infused over 12 hours.
Study: NCT01153828
Drug: Retapamulin
Normalized name: Retapamulin
DrugBank: Retapamulin (DB01256)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prescription for retapamulin
Study: NCT01153828
Drug: Co-prescription of retapamulin and topical mupirocin
Normalized name: retapamulin Topical Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Same day prescriptions for retapamulin and topical mupirocin
Study: NCT01153828
Drug: Co-prescription of retapamulin and topical fusidic acid
Normalized name: retapamulin Topical Ointment
DrugBank: Retapamulin (DB01256)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Same day prescription for retapamulin and fusidic acid.
Study: NCT02841761
Drug: Midalozam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Syrup for oral use
Study: NCT02841761
Drug: Aprocitentan
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral use
Study: NCT00380874
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150- 600 mg/day (double blind in divided doses)
Study: NCT03380429
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
Study: NCT03751176
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
Study: NCT03751176
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1
Study: NCT03751176
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
Study: NCT03751176
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
Study: NCT01215136
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
Study: NCT01215136
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
Study: NCT02816736
Drug: valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.~The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).
Study: NCT02816736
Drug: valsartan placebo
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)
Study: NCT03303235
Drug: Methylergonovine
Normalized name: methylergonovine
DrugBank: Methylergometrine (DB00353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV vs IM
Study: NCT02912702
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2000U/m2 day5
Study: NCT02912702
Drug: doxorubicin hydrochloride liposome injection
Normalized name: doxorubicin hydrochloride liposome Injection
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 day 1
Study: NCT02912702
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2 was administered once on the first day of every week
Study: NCT02912702
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
Study: NCT02912702
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2 twice weekly for 2 weeks and then weekly
Study: NCT02912702
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
Study: NCT03427242
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral apatinib 750mg qd
Study: NCT01236716
Drug: Albumin paclitaxel plus carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
Study: NCT01236716
Drug: Gemcitabine plus carboplatin
Normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive carboplatin AUC=5 q3w and gemcitabine 1250 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
Study: NCT03699332
Drug: Indium-111-DOTA-Labetuzumab-IRDye800CW injection
DrugBank: Labetuzumab (DB05097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tracer injection
Study: NCT01515423
Drug: Placebo (20% Intralipid)
Normalized name: soybean oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
Study: NCT01722708
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole 500 Milligrams\*2/Day for a week
Study: NCT03197623
Drug: LLP2A-ALENDRONATE
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.
Study: NCT01707290
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg tablet, oral use, every 12 hours (q12h)
Study: NCT00097448
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, 19 days
Study: NCT00097448
Drug: methylprednisolone sodium succinate
Normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four intratympanic injections delivered to the middle ear over 2 weeks
Study: NCT02500095
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant saline during fasting
Study: NCT02500095
Drug: Pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concomitant Growth hormone receptor blockade with Pegvisomant during fasting
Study: NCT04535141
Drug: Olanzapine 5 MG
Normalized name: olanzapine 5 MG
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will be a de-identified pill created by investigational drug services at University of North Carolina
Study: NCT01268670
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive topical LET and oral oxycodone.
Study: NCT02401269
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01015534
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01075789
Drug: Lignocaine
Normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
Study: NCT01059656
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
Study: NCT01932333
Drug: JNJ-40411813 50 mg
Normalized name: JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).